Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

pSivida reports 6-month interim readout of the human PK Iluvien study

Oct. 6, 2008

Potentia presents positive safety data in phase I POT-4 trial

Oct. 1, 2008

Quark developing QPI-1007 as neuroprotective agent for eye diseases

Oct. 1, 2008

CHMP recommends marketing authorization for Azarga in open-angle glaucoma

Sep. 30, 2008

Regression of corneal neovascularization with novel antisense oligonucleotide GS-101

Sep. 30, 2008

Independent Data Safety Monitoring supports continuation of Iluvien trial

Sep. 29, 2008

Inspire requests SPA process for Prolacria for dry eye

Sep. 29, 2008

Othera commences phase I/II OT-730 trial in ocular hypertension and glaucoma

Sep. 17, 2008

New compounds for treating glaucoma disclosed in recent Allergan patent

Sep. 17, 2008

Inspire plans clinical testing of new glaucoma compound INS-117548

Sep. 17, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 27, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 27, 2025
New drugs with the same old resistance tricks?
BioWorld
According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in 2020. And figures are rising, with...
OS Therapies heading to FDA with positive osteosarcoma data
BioWorld
With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing...
Vilastobart set apart? Xilio phase II combo performs in CRC
BioWorld
“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...